share_log

ReShape Lifesciences Expects 2024 Operating Expenses To Decrease By More Than 50% Compared to 2023; Reaffirming Commitment To Profitability

Benzinga ·  Apr 2 04:09
ReShape Lifesciences Expects 2024 Operating Expenses To Decrease By More Than 50% Compared to 2023; Reaffirming Commitment To Profitability
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment